Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
GW Pharmaceuticals has sold the rare-disease priority review voucher (PRV) it obtained with US Food and Drug Administration approval of its epilepsy treatment Epidiolex. PRVs, introduced by the FDA to spur research into rare and tropical diseases, are granted when a drug for an underserved disease is approved. They can be used to speed the agency’s review of another new drug application. GW got $105 million for its voucher from Biohaven Pharmaceuticals, which will use it to expedite the review of a migraine therapy.
This article has been sent to the following recipient: